



Image

1647

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)		Application Number	09/869,414
		Filing Date	June 27, 2001
		First Named Inventor	Mark E. Gurney
		Art Unit	1647
		Examiner Name	C. Nichols
Total Number of Pages in This Submission	1	Attorney Docket Number	29915/6280M

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form  <input checked="" type="checkbox"/> Fee Attached  <input checked="" type="checkbox"/> Amendment/Reply  <input type="checkbox"/> After Final  <input type="checkbox"/> Affidavits/declaration(s)  <input checked="" type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Response to Missing Parts/Incomplete Application  <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s)  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition  <input type="checkbox"/> Petition to Convert to a Provisional Application  <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):  Substitute Sequence Listing, Diskette, Sequence Statement
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	MARSHALL, GERSTEIN & BORUN LLP Sharon M. Sintich - 48,484
Signature	
Date	January 5, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: January 5, 2004

Signature:

(Sharon M. Sintich)

hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: January 5, 2004

Signature:

(Sharon M. Smith)

Docket No.: 29915/6280M

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Patent Application of:

Mark E. Gurney, et al

Application No.: 09/869,414

Group Art Unit: 1647

Filed: June 27, 2001

Examiner: Nichols, Christopher

For: ALZHEIMER'S DISEASE SECRETASE, APP  
SUBSTRATES THEREFOR, AND USES  
THEREFOR

**AMENDMENT AND REQUEST FOR RECONSIDERATION**

Commissioner for Patents  
Alexandria, VA 22313

Dear Sir:

This amendment is in response to the Office Action mailed September 5, 2003. Claims 151-169 were variously rejected under 35 U.S.C. § 102(b) and § 112, first and second paragraphs. Claims 151, 155, 161 and 162 were also provisionally rejected for double patenting. Reconsideration and withdrawal of the rejections are respectfully requested in light of the following amendment and remarks. This response is timely filed with a petition and fee for one-month extension of time.

**Amendments to the Specification** begin at page 2 of this paper.

**Amendments to the Sequence Listing** begin at page 3 of this paper.

**Amendments to the Claims** begin at page 4 of this paper.

**Remarks** begin at page 11 of this paper.